Finally, we believe it is very important to take the current health context into account, where new molecules are being developed for the treatment of thrombotic and embolic diseases. Thus, the results obtained to date with the xi-melagatran, an oral prodrug of melagatran (direct coagulation inhibitor), are promising, and different Phase III studies have been successfully completed, with commercialisation scheduled for the coming months.